89Bio Inc ETNB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
8.10UNCH (UNCH)
Volume
26,073
Close
8.10UNCH (UNCH)
Volume
818,572
52 week range
6.57 - 22.93
Loading...
  • Open7.96
  • Day High8.31
  • Day Low7.82
  • Prev Close8.10
  • 52 Week High22.93
  • 52 Week High Date06/13/23
  • 52 Week Low6.57
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap796.91M
  • Shares Out98.38M
  • 10 Day Average Volume1.15M
  • Dividend-
  • Dividend Yield-
  • Beta1.00
  • YTD % Change-27.48

KEY STATS

  • Open7.96
  • Day High8.31
  • Day Low7.82
  • Prev Close8.10
  • 52 Week High22.93
  • 52 Week High Date06/13/23
  • 52 Week Low6.57
  • 52 Week Low Date10/23/23
  • Market Cap796.91M
  • Shares Out98.38M
  • 10 Day Average Volume1.15M
  • Dividend-
  • Dividend Yield-
  • Beta1.00
  • YTD % Change-27.48

RATIOS/PROFITABILITY

  • EPS (TTM)-2.01
  • P/E (TTM)-4.03
  • Fwd P/E (NTM)-3.49
  • EBITDA (TTM)-179.912M
  • ROE (TTM)-34.51%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)4.89%

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On 89Bio Inc

 

Profile

MORE
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG)....
Steven Altschuler M.D.
Independent Chairman of the Board of Director
Rohan Palekar
Chief Executive Officer, Director
Ryan Martins
Chief Financial Officer
Quoc Le-Nguyen
Chief Technical Operations Officer and Head of Quality
Address
142 Sansome Street, Second Floor
San Francisco, CA
94104
United States

Top Peers

SYMBOLLASTCHG%CHG
PRME
Prime Medicine Inc
6.57-0.32-4.64%
COGT
Cogent Biosciences Inc
8.39-0.02-0.24%
VRDN
Viridian Therapeutics Inc
12.17-0.06-0.49%
SRRK
Scholar Rock Holding Corp
9.51+0.08+0.85%
LBPH
Longboard Pharmaceuticals Inc
17.55-0.19-1.07%